L M Ruilope
Overview
Explore the profile of L M Ruilope including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
266
Citations
1509
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sanz-Gomez M, Manzano-Lista F, Vega-Martin E, Gonzalez-Moreno D, Alcala M, Gil-Ortega M, et al.
Biomed Pharmacother
. 2023 Oct;
168:115661.
PMID: 37832406
The non-steroidal mineralocorticoid receptor antagonist (MRA) finerenone (FIN) improves kidney and cardiovascular outcomes in patients with chronic kidney disease (CKD) in type 2 diabetes (T2D). We explored the effect of...
2.
Carasol M, Munoz Aguilera E, Ruilope L
Hipertens Riesgo Vasc
. 2023 May;
40(4):167-170.
PMID: 37173185
No abstract available.
3.
Ruilope L, Ruiz-Hurtado G
Hipertens Riesgo Vasc
. 2022 Dec;
40(2):55-57.
PMID: 36529615
No abstract available.
4.
Gorostidi M, Gijon-Conde T, de la Sierra A, Rodilla E, Rubio E, Vinyoles E, et al.
Hipertens Riesgo Vasc
. 2022 Sep;
39(4):174-194.
PMID: 36153303
Hypertension is the most important risk factor for global disease burden. Detection and management of hypertension are considered as key issues for individual and public health, as adequate control of...
5.
Gijon-Conde T, Rubio E, Gorostidi M, Vinyoles E, Armario P, Rodilla E, et al.
Hipertens Riesgo Vasc
. 2021 Apr;
38(4):186-196.
PMID: 33888438
The pandemic caused by coronavirus SARS-CoV-2 (COVID-19) has forced, in many cases, to replace face-to-face consultation with the telematic consultation, in order to reduce the risk of contagion associated with...
6.
Gijon-Conde T, Rodilla E, Molinero A, Alvargonzalez M, Ruilope L
Hipertens Riesgo Vasc
. 2020 Aug;
38(1):4-12.
PMID: 32807680
Objective: To analyse the data, according to recruiting place and sex, of the survey May Measure Month in 2018 (MMM18) in Spain, promoted by the International Society of Hypertension. Methods:...
7.
Ruilope L, Garcia Donaire J, de la Sierra A
Hipertens Riesgo Vasc
. 2020 May;
37(3):99-100.
PMID: 32448641
No abstract available.
8.
Ruilope L, Ruiz-Hurtado G
J Hum Hypertens
. 2020 May;
34(8):557-559.
PMID: 32376997
Arterial hypertension is particularly prevalent in the elderly and treatment is required according to the literature. Treatment in subjects between 65 and 80 years of age resembles by characteristics and...
9.
Corbacho-Alonso N, Rodriguez-Sanchez E, Martin-Rojas T, Mourino-Alvarez L, Sastre-Oliva T, Hernandez-Fernandez G, et al.
Expert Rev Proteomics
. 2019 Jun;
16(7):583-591.
PMID: 31195841
: Hypertension is a multifactorial disease that has, thus far, proven to be a difficult target for pharmacological intervention. The application of proteomic strategies may help to identify new biomarkers...
10.
Gijon-Conde T, Gorostidi M, Banegas J, de la Sierra A, Segura J, Vinyoles E, et al.
Hipertens Riesgo Vasc
. 2019 Jun;
36(4):199-212.
PMID: 31178410
Conventional blood pressure (BP) measurement in clinical practice is the most used procedure for the diagnosis and treatment of hypertension (HT), but is subject to considerable inaccuracies due to, on...